Guideline for the diagnosis and management of hyperuricemia and gout in China(2019)
中国高尿酸血症与痛风诊疗指南(2019)(43283)
The ACE trial: a new perspective on the effect of acarbose on cardiovascular outcomes
ACE研究:阿卡波糖对心血管结局影响的新视角(33723)
Implications and challenges of the ACE trial
ACE研究的启示和挑战(30276)
Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis
中国甲状腺功能亢进症和其他原因所致甲状腺毒症诊治指南(27349)
Value of individualized, patient-centered use of short-acting glucagon-like peptide-1 receptor agonist lixisenatide for the treatment of type 2 diabetes mellitus
短效胰升糖素样肽1受体激动剂利司那肽在2型糖尿病个体化治疗中的价值(26191)
Individualized, patient-centered use of lixisenatide for the treatment of type 2 diabetes mellitus
利司那肽在2型糖尿病个体化治疗中的应用(25655)
Chinese Journal of Endocrinology and Metabolism uses the remote manuscript management system of Chinese Medical Association Series Periodicals, whereby the manuscript is reviewed through a three-stage process based on a peer-review system (editorial review, external review by experts, final review by the Editorial Committee). Manuscripts that fail to meet the requirements in the preliminary review or are deemed to have no publication value will be rejected. Manuscripts that need to be reviewed externally will be submitted for expert review and handled according to privacy and confidentiality principles. Each manuscript is reviewed at least by two experts. After the external review, the Editor will determine whether the manuscript will be rejected or returned for revision. The Editorial Committee will make the final decision whether the revised manuscript will be accepted, further revised or rejected.